Bristol Myers Squibb Reports Positive Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy BMY?
Source: NASDAQ.COM
- Successful Clinical Trial: Bristol Myers Squibb's SUCCESSOR-2 study shows that oral mezigdomide combined with carfilzomib and dexamethasone significantly improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, indicating the combination therapy's clinical significance.
- Safety Consistency: The safety findings align with the known profile of mezigdomide, suggesting good safety in combination therapy, with patients continuing to be monitored for survival and safety to ensure long-term efficacy.
- Study Design Features: The SUCCESSOR-2 study is a multicenter, randomized, open-label Phase 2/3 trial primarily assessing the efficacy and safety of mezigdomide, with PFS as the primary endpoint, providing crucial evidence for future clinical applications.
- Key Secondary Endpoints: The study also focuses on several key secondary endpoints, including overall survival (OS) and overall response rate (ORR), which will further evaluate the comprehensive efficacy of the treatment regimen and its impact on patient quality of life, holding significant clinical value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.310
Low
37.00
Averages
55.86
High
68.00
Current: 58.310
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bloomsbury Publishing Reports 7% Profit Increase and Dividend Boost
- Significant Profit Growth: Bloomsbury Publishing PLC reported a 7% increase in profits to £44.9 million, supporting a 5% dividend increase, demonstrating the company's resilience through diversified revenue streams, particularly in consumer and academic publishing.
- Doubling Academic Revenue: The academic and professional division generated £108 million in revenue with profits doubling to £25 million, indicating strong growth driven by digital sales, particularly in the expanding Asian market, which positions the company for further expansion.
- AI Licensing Agreement Potential: The partnership with Google for AI licensing is expected to enhance operational efficiency, although challenges exist in the AI market; the high-quality academic content will support future AI model training, strengthening the company's competitive edge.
- Optimistic Book Release Outlook: Pre-orders for upcoming releases from bestselling author Sarah J. Maas are extraordinarily high, reflecting robust market demand, which is anticipated to drive record profits in the coming year, further solidifying Bloomsbury's position in the publishing industry.
See More
BioArctic AB Reports Strong Earnings, Positive Outlook for Leqembi Sales
- Strong Financial Performance: BioArctic AB (BRCTF) reported over EUR 500 million in sales through its partner ACI for the fiscal year, indicating significant market potential in Alzheimer's treatment, with Leqembi sales expected to exceed USD 900 million in 2026, further solidifying its market position.
- Increased R&D Investment: The company anticipates a 40% to 60% rise in R&D spending compared to last year, primarily directed towards programs nearing IND-enabling stages, particularly the Ixidabumab project related to Parkinson's disease, which will enhance future product development and market competitiveness.
- Market Access Challenges: Despite facing challenges in market access for Leqembi in Sweden due to conservative health economic modeling assumptions, the company is actively exploring alternative pathways to ensure patient access, demonstrating its strong commitment to the market.
- Robust Financial Position: BioArctic AB currently holds over 2 billion Swedish crowns in cash reserves, which not only secures ongoing investments in projects but also lays the groundwork for potential dividend payments in the future, thereby boosting investor confidence.
See More
Bristol Myers Squibb Partners with Anthropic to Deploy Claude AI
- Partnership Announcement: Bristol Myers Squibb has partnered with AI company Anthropic to make its Claude AI model available to over 30,000 employees, aiming to enhance the efficiency of drug discovery and development.
- Technology Implementation: By integrating Claude AI, Bristol Myers Squibb seeks to accelerate the processes of discovering, developing, and delivering new medicines, thereby maintaining its competitive edge in the pharmaceutical industry.
- Employee Empowerment: This collaboration not only equips employees with advanced AI tools but also fosters cross-departmental collaboration, enhancing overall work efficiency and driving the company's innovation capabilities.
- Market Impact: With the application of AI technology, Bristol Myers Squibb is expected to shorten drug time-to-market, strengthening its competitive position in the biopharmaceutical sector and addressing the growing patient demand.
See More
Bristol-Myers Squibb Expands AI Applications with Anthropic's Claude Platform
- AI Platform Rollout: Bristol-Myers Squibb is rolling out Anthropic's Claude AI platform to over 30,000 employees, marking a significant enhancement in the application of artificial intelligence across research, clinical development, and corporate operations, which is expected to substantially improve efficiency and decision-making quality.
- Intelligent Workflows: By integrating Claude's agentic capabilities into daily workflows, BMS can not only generate clinical study reports in real-time but also extract scientific context from decades of internal research, thereby enhancing the depth and breadth of scientific inquiry.
- Accelerated Software Development: The company is also utilizing Claude Code to expedite software and AI development, which is anticipated to shorten development cycles and improve time-to-market, further strengthening its competitive position in the biopharmaceutical sector.
- Industry Collaboration Outlook: This partnership not only enhances BMS's AI capabilities but also contrasts with collaborations by competitors like OpenAI, indicating that the application of AI technology is becoming a key driver of industry development in the biotechnology field.
See More
Three High-Yield Safe Stocks to Consider
- Target Stock Recovery: Target's stock has risen 25% this year, yet it remains down over 40% in the past five years, indicating a significant valuation gap compared to rival Walmart, with expectations for future price increases, although economic conditions may delay this rebound.
- Bristol Myers Dividend Advantage: Bristol Myers offers a dividend yield of 4.4%, significantly higher than the S&P 500's 1.1%, and despite a 12% decline in stock price over the past five years, its free cash flow of $11.9 billion suggests it can sustain dividends while reducing debt.
- General Mills High-Yield Challenges: General Mills boasts a 7.4% dividend yield, but its stock has fallen 47% over the past five years, with projected organic net sales declines of 1.5% to 2% for the upcoming fiscal year; however, its free cash flow of $1.7 billion is sufficient to cover dividend payments, indicating financial resilience.
- Market Uncertainty: While all three stocks face unique challenges, the undervaluation of Target and Bristol Myers, along with their stable dividend payments, makes them attractive for long-term investment, particularly in the context of potential economic recovery.
See More
US Supreme Court Rejects Pharma Challenge to Medicare Drug Price Negotiation Plan
- Supreme Court Ruling: The US Supreme Court declined to hear the pharmaceutical industry's challenge to the Biden administration's drug price negotiation plan, upholding lower court decisions and reinforcing the government's legal stance on controlling drug prices.
- Drug Price Negotiation Plan: This initiative aims to reduce prescription costs for Medicare beneficiaries by requiring drugmakers to negotiate maximum prices for specific medications with the Centers for Medicare & Medicaid Services, with steep daily taxes for non-compliance.
- Industry Opposition: Six companies, including Novo Nordisk and AstraZeneca, filed lawsuits claiming the plan violates the Constitution, arguing it is not a genuine negotiation but rather a government-imposed price control that could hinder innovation.
- Legal Implications: Despite multiple lawsuits, the first negotiated prices for ten drugs took effect this year, demonstrating the government's commitment to controlling drug costs, which may directly impact out-of-pocket expenses for patients.
See More
Bloomsbury Publishing Reports 7% Profit Increase and Dividend Boost
- Significant Profit Growth: Bloomsbury Publishing PLC reported a 7% increase in profits to £44.9 million, supporting a 5% dividend increase, demonstrating the company's resilience through diversified revenue streams, particularly in consumer and academic publishing.
- Doubling Academic Revenue: The academic and professional division generated £108 million in revenue with profits doubling to £25 million, indicating strong growth driven by digital sales, particularly in the expanding Asian market, which positions the company for further expansion.
- AI Licensing Agreement Potential: The partnership with Google for AI licensing is expected to enhance operational efficiency, although challenges exist in the AI market; the high-quality academic content will support future AI model training, strengthening the company's competitive edge.
- Optimistic Book Release Outlook: Pre-orders for upcoming releases from bestselling author Sarah J. Maas are extraordinarily high, reflecting robust market demand, which is anticipated to drive record profits in the coming year, further solidifying Bloomsbury's position in the publishing industry.
See More
BioArctic AB Reports Strong Earnings, Positive Outlook for Leqembi Sales
- Strong Financial Performance: BioArctic AB (BRCTF) reported over EUR 500 million in sales through its partner ACI for the fiscal year, indicating significant market potential in Alzheimer's treatment, with Leqembi sales expected to exceed USD 900 million in 2026, further solidifying its market position.
- Increased R&D Investment: The company anticipates a 40% to 60% rise in R&D spending compared to last year, primarily directed towards programs nearing IND-enabling stages, particularly the Ixidabumab project related to Parkinson's disease, which will enhance future product development and market competitiveness.
- Market Access Challenges: Despite facing challenges in market access for Leqembi in Sweden due to conservative health economic modeling assumptions, the company is actively exploring alternative pathways to ensure patient access, demonstrating its strong commitment to the market.
- Robust Financial Position: BioArctic AB currently holds over 2 billion Swedish crowns in cash reserves, which not only secures ongoing investments in projects but also lays the groundwork for potential dividend payments in the future, thereby boosting investor confidence.
See More
Bristol Myers Squibb Partners with Anthropic to Deploy Claude AI
- Partnership Announcement: Bristol Myers Squibb has partnered with AI company Anthropic to make its Claude AI model available to over 30,000 employees, aiming to enhance the efficiency of drug discovery and development.
- Technology Implementation: By integrating Claude AI, Bristol Myers Squibb seeks to accelerate the processes of discovering, developing, and delivering new medicines, thereby maintaining its competitive edge in the pharmaceutical industry.
- Employee Empowerment: This collaboration not only equips employees with advanced AI tools but also fosters cross-departmental collaboration, enhancing overall work efficiency and driving the company's innovation capabilities.
- Market Impact: With the application of AI technology, Bristol Myers Squibb is expected to shorten drug time-to-market, strengthening its competitive position in the biopharmaceutical sector and addressing the growing patient demand.
See More
Bristol-Myers Squibb Expands AI Applications with Anthropic's Claude Platform
- AI Platform Rollout: Bristol-Myers Squibb is rolling out Anthropic's Claude AI platform to over 30,000 employees, marking a significant enhancement in the application of artificial intelligence across research, clinical development, and corporate operations, which is expected to substantially improve efficiency and decision-making quality.
- Intelligent Workflows: By integrating Claude's agentic capabilities into daily workflows, BMS can not only generate clinical study reports in real-time but also extract scientific context from decades of internal research, thereby enhancing the depth and breadth of scientific inquiry.
- Accelerated Software Development: The company is also utilizing Claude Code to expedite software and AI development, which is anticipated to shorten development cycles and improve time-to-market, further strengthening its competitive position in the biopharmaceutical sector.
- Industry Collaboration Outlook: This partnership not only enhances BMS's AI capabilities but also contrasts with collaborations by competitors like OpenAI, indicating that the application of AI technology is becoming a key driver of industry development in the biotechnology field.
See More
Three High-Yield Safe Stocks to Consider
- Target Stock Recovery: Target's stock has risen 25% this year, yet it remains down over 40% in the past five years, indicating a significant valuation gap compared to rival Walmart, with expectations for future price increases, although economic conditions may delay this rebound.
- Bristol Myers Dividend Advantage: Bristol Myers offers a dividend yield of 4.4%, significantly higher than the S&P 500's 1.1%, and despite a 12% decline in stock price over the past five years, its free cash flow of $11.9 billion suggests it can sustain dividends while reducing debt.
- General Mills High-Yield Challenges: General Mills boasts a 7.4% dividend yield, but its stock has fallen 47% over the past five years, with projected organic net sales declines of 1.5% to 2% for the upcoming fiscal year; however, its free cash flow of $1.7 billion is sufficient to cover dividend payments, indicating financial resilience.
- Market Uncertainty: While all three stocks face unique challenges, the undervaluation of Target and Bristol Myers, along with their stable dividend payments, makes them attractive for long-term investment, particularly in the context of potential economic recovery.
See More
US Supreme Court Rejects Pharma Challenge to Medicare Drug Price Negotiation Plan
- Supreme Court Ruling: The US Supreme Court declined to hear the pharmaceutical industry's challenge to the Biden administration's drug price negotiation plan, upholding lower court decisions and reinforcing the government's legal stance on controlling drug prices.
- Drug Price Negotiation Plan: This initiative aims to reduce prescription costs for Medicare beneficiaries by requiring drugmakers to negotiate maximum prices for specific medications with the Centers for Medicare & Medicaid Services, with steep daily taxes for non-compliance.
- Industry Opposition: Six companies, including Novo Nordisk and AstraZeneca, filed lawsuits claiming the plan violates the Constitution, arguing it is not a genuine negotiation but rather a government-imposed price control that could hinder innovation.
- Legal Implications: Despite multiple lawsuits, the first negotiated prices for ten drugs took effect this year, demonstrating the government's commitment to controlling drug costs, which may directly impact out-of-pocket expenses for patients.
See More
